<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-one patients with a median age of 9 years (0.5-19) underwent intensified myeloblative therapy: 1800 mg/m2 etoposide (VP) was added to 120 mg/kg <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) and 12 Gy fractionated total body irradiation (FTBI) or 12-16 mg/kg <z:chebi fb="0" ids="28901">busulfan</z:chebi> (BU) for treatment of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (11 patients), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (8 patients), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (1 patient), or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (1 patient) </plain></SENT>
<SENT sid="1" pm="."><plain>Severe liver toxicity occurred in 5 of 7 children (71%) receiving short-term <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) and additional <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CSA) for prophylaxis of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="2" pm="."><plain>Three of them died of subsequent <z:hpo ids='HP_0001919'>acute renal failure</z:hpo> on days 8, 13, and 34 </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, <z:hpo ids='HP_0011009'>acute</z:hpo> severe organ toxicity occurred in only 1 of 14 children (7%) receiving the same intensified regimens who were autografted (7 pts) or received MTX alone for GVHD prophylaxis (7 pts) </plain></SENT>
<SENT sid="4" pm="."><plain>These observations suggest that GVHD prophylaxis with MTX and CSA may adversely influence the tolerance of intensified antileukemic regimens in children </plain></SENT>
</text></document>